Skip to main content

Advertisement

Peer Review reports

From: Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Original Submission
25 Jan 2016 Submitted Original manuscript
14 May 2016 Reviewed Reviewer Report - Guohui Wan
18 May 2016 Reviewed Reviewer Report - Venkata Parsa
25 Jun 2016 Author responded Author comments - Mengxia Li
Resubmission - Version 2
25 Jun 2016 Submitted Manuscript version 2
8 Nov 2016 Author responded Author comments - Mengxia Li
Resubmission - Version 3
8 Nov 2016 Submitted Manuscript version 3
13 Feb 2017 Author responded Author comments - Mengxia Li
Resubmission - Version 4
13 Feb 2017 Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
21 Feb 2017 Author responded Author comments - Mengxia Li
Resubmission - Version 6
21 Feb 2017 Submitted Manuscript version 6
Publishing
2 Mar 2017 Editorially accepted
4 Apr 2017 Article published 10.1186/s12885-017-3165-0

You can find further information about peer review here.

Back to article page